Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study.

Thumbnail
Date
2021
Author
Maio, Michele
Shapira-Frommer, Ronnie
Yap, Timothy A.
Ciuleanu, Tudor
Gomez, Henry
Hill, Andrew
Lugowska, Iwona
Ozyilkan, Ozgur
Vera, Karina
Im, Seock-Ah
Kryzhanivska, Anna
Lysenko, Serhii
Schenker, Michael
Stemmer, Salomon M.
Saraf, Sanatan
Cristescu, Razvan
Jin, Fan
Gozmen, Alexander
Quintela-Fandino, Miguel
Metadata
Show full item record
URI
http://hdl.handle.net/11727/7418
Collections